Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer
Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...
Company
Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center
The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China,...
United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion
Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...
Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center
US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...
Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D
China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million)...
Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery
Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...
LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM
China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III...
Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...
Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...
Everest Medicines’ Xerava NDA Accepted by Taiwan’s TFDA
Everest Medicines (HKG: 1952) announced that its New Drug Application (NDA) for Xerava (eravacycline) for...
China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...
HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...
NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review
The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...
NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme
The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing...
FibroGen’s Roxadustat Sales in China Rise Despite Price Cut
US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its...
Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study
China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...
Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...
Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial
China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...